Mary T Szela
CIK 1410289 · CEO and President · last filed 2026-07-06
Mary T Szela is a CEO and President who has filed 80 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing shows the insider bought $148.9K of ABSI on Jul 6, 2026. Across all open-market trades the lifetime net is −$7.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $24.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$24.22M
12
80
-$7.54M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABSI | Director | 21,300 | $7.13 | $151.9K | $148.9K | 4 | 2026-07-06 |
| TLSI | CEO and President | 1,077,683 | $4.33 | $4.67M | $0 | 1 | 2026-07-01 |
| KURA | Director | — | $9.31 | — | $0 | 9 | 2026-06-04 |
| TLSIW | CEO and President | 1,065,215 | $0.88 | $937.4K | $350.7K | 10 | 2026-05-18 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 3 | 2024-06-21 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Director | 0 | $199.92 | $0 | $0 | 4 | 2023-06-16 |
| CHRS | Director | 0 | $1.44 | $0 | -$966.8K | 9 | 2021-01-13 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | — | $5.54 | — | $0 | 3 | 2020-06-22 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Chief Executive Officer | 4,384 | — | — | $0 | 2 | 2017-05-11 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Chief Executive Officer | — | — | — | $0 | 3 | 2016-11-30 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 3 | 2015-08-27 |
| ABT | Senior Vice President | 172,123 | $107.27 | $18.46M | -$7.07M | 27 | 2011-12-16 |
Recent Filings
80 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | ABSI | Buy (P) | +12,900 | $148.9K | EDGAR |
| 2026-07-01 | TLSI | Grant (A) | +3,990 | $15.4K | EDGAR |
| 2026-06-15 | ABSI | Grant (A) | +8,400 | $0 | EDGAR |
| 2026-06-08 | ABSI | Grant (A) | +10,100 | $0 | EDGAR |
| 2026-06-04 | KURA | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | TLSIW | Buy (P) | +39,682 | $102.8K | EDGAR |
| 2026-03-20 | TLSIW | Sell (S) | −20,302 | -$79.4K | EDGAR |
| 2026-02-23 | TLSIW | Buy (P) | +30,487 | $125.0K | EDGAR |
| 2025-11-25 | TLSIW | Grant (A) | +550,000 | $0 | EDGAR |
| 2025-07-09 | ABSI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.